Valproic acid enhances CAR-T cell recognition of tumor targets and cytotoxic effects by upregulating the expression of NKG2D ligands (ULBP1-3) on tumor cell surfaces and activating the NKG2D-NKG2DL immune recognition axis (71). Here, KLRK1 is linked to neoplasm.